A deficiency of the antioxidant coenzyme Q10 may be associated with long-term
conditions including heart disease and high blood pressure. Symptoms of
deficiency include gingivitis, and weakened immune
The selected depletions information presented here identifies some of the
nutrients that may be depleted by certain medications. The signs and symptoms
associated with nutrient deficiency may also indicate conditions other than
nutrient deficiency. If you are experiencing any of the signs or symptoms
mentioned, it does not necessarily mean that you are nutrient deficient.
Nutrient depletion depends upon a number of factors, including your medical
history, diet, and lifestyle as well as the length of time you have been taking
the medication. Please consult your healthcare provider; he or she can best
assess and address your individual healthcare needs, and determine if you are at
risk for nutrient depletions from these medications as well as others not listed
Belichard P, Pruneau D, Zhiri A. Effect of a long-term treatment with
lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in
cardiomyopathic hamster. Biochim Biophys Acta. 1993;1169(1):98-102.
Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting
coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors
(statins): A critical review. Adv Ther. 1998;15(4):218-228.
Chan A, Reichmann H, Kogel A, et al. Metabolic changes in patients with
mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol.
De Pinieux G, et al. Lipid-lowering drugs and mitochondrial function: effects
of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate
Br J Clin Pharmacol. 1996;42(3):333-337.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q
levels in humans. Proc Natl Acad SciUSA.
Folkers K, Morita M, McRee J Jr. The activities of coenzyme Q10 and vitamin
B6 for immune responses. Biochem Biophys Res Commun. 1993;
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering
effect of HMG-CoA reductase inhibitors: a double-blind, placebo-controlled
study. J Clin Pharmacol. 1993;33(3):226-229.
Hanaki Y, Sugiyama S, Ozawa T, Ohno M. Coenzyme Q10 and coronary artery
disease. Clin Invest. 1993;71(8 Suppl):S112-S115.
Kaikkonen J, Nyyssonen K, Tuomainen TP, et al. Determinants of plasma
coenzyme Q10 in humans. FEBSLett. 1999;443(2):163-166.
Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on
exercise tolerance in chronic stable angina pectoris. Am J Cardiol.
Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone
concentrations after short- and long-term treatment with HMG-CoA reductase
inhibitors. Eur J Clin Pharmacol. 1994;46(4):313-317.
Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum
coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects
Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart
failure. Biofactors. 1999;9(2-4):285-289.
Nakamura R, Littarru GP, Folkers R, et al. Study of CoQ10-enzymes in gingiva
from patients with periodontal disease and evidence for a deficiency of coenzyme
Q10. Proc Natl Acad SciUSA. 1974;71(4):1456-1460.
Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on
blood pressure and insulin resistance in hypertensive patients with coronary
heart disease. J Hum Hypertens. 1999;13(3):203-208.
Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind
placebo-controlled trial of coenzyme Q10 in patients with acute myocardial
infarction. Cardiovasc Drugs Ther. 1998;12(4):347-353.
Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone)
concentrations in patients with simvastatin. J Clin Pathol.
Review Date: October 2000
Reviewed By: All depletions monographs have been reviewed by a team of experts including
Derrick M. DeSilva, Jr., MD, Raritan Bay Medical Center, Perth Amboy, NJ;
Jacqueline A. Hart, MD, Department of Internal Medicine, Newton-Wellesley
Hospital, Harvard University and Senior Medical Editor, A.D.A.M., Inc., Boston,
MA; John Hinze, PharmD, NMD, Woodbine, IA; Ruth Marlin, MD, Medical Director and
Director of Medical Education, Preventive Medicine Research Institute,
Sausalito, CA; Brian T Sanderoff, PD, BS in Pharmacy, Clinical Assistant
Professor, University of Maryland School of Pharmacy; President, Your
Prescription for Health, Owings Mills, MD; Leonard Wisneski, MD, FACP, George
Washington University, Rockville, MD; Ira Zunin, MD, MPH, MBA, President and
Chairman, Hawaii State Consortium for Integrative Medicine, Honolulu,
The publisher does not accept any responsibility for the accuracy of
the information or the consequences arising from the application, use, or misuse
of any of the information contained herein, including any injury and/or damage
to any person or property as a matter of product liability, negligence, or
otherwise. No warranty, expressed or implied, is made in regard to the contents
of this material. No claims or endorsements are made for any drugs or compounds
currently marketed or in investigative use. This material is not intended as a
guide to self-medication. The reader is advised to discuss the information
provided here with a doctor, pharmacist, nurse, or other authorized healthcare
practitioner and to check product information (including package inserts)
regarding dosage, precautions, warnings, interactions, and contraindications
before administering any drug, herb, or supplement discussed